Sugammadex and Smoker's Neuromuscular Block

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

We compared the durations of antagonizing and of the severity of effect of sugammadex used in antagonizing the rocuronium in smoker and non-smoker total 40 patients with using Train of Four(TOF) neuromuscular monitorization.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duzce University

Criteria

Inclusion Criteria:

• Elective surgery,

• 1-2 according to the ASA ( American Society of Anesthesiologist ) physical status classification.

• Patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking

• Or never smoked patients

Exclusion Criteria:

• neuromuscular diseases

• radiotherapy and/or chemotherapy anamnesis,

• liver and/or renal disease,

• electrolyte balance,

• history of drug use which affects neuromuscular transmission,

• Body Mass Index (BMI) of more than 27,

• use alcohol